Clinical Trials Logo

Cystitis, Interstitial clinical trials

View clinical trials related to Cystitis, Interstitial.

Filter by:

NCT ID: NCT05744908 Completed - Clinical trials for Chronic Interstitial Cystitis

Pentosan Polysulfate Treatment's Effectiveness

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).

NCT ID: NCT05740007 Recruiting - Clinical trials for Interstitial Cystitis

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Start date: March 28, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance.

NCT ID: NCT05737121 Recruiting - Clinical trials for Interstitial Cystitis

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Start date: May 22, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) / bladder pain syndrome (BPS).

NCT ID: NCT05726786 Recruiting - Bladder Cancer Clinical Trials

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

INCyst
Start date: April 10, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy. As a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN. This is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.

NCT ID: NCT05699551 Recruiting - Clinical trials for Interstitial Cystitis

Supervised Exercise as a Therapeutic Strategy for Interstitial Cystitis/Bladder Pain Syndrome

IC/BPS
Start date: May 10, 2023
Phase: N/A
Study type: Interventional

In this study, the efficacy of exercise to improve interstitial cystitis/bladder pain syndrome symptoms and quality of life will be investigated.

NCT ID: NCT05658874 Recruiting - Clinical trials for Interstitial Cystitis

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Start date: December 1, 2022
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare two different treatment patterns in patients with chronic bladder pain. The main questions the investigators are seeking to answer is if bladder pain improves before and after treatment using a painful bladder scale. The participant will have 5 visits to evaluate your symptoms with questionnaires, at least one procedural visit, and must participate in physical therapy and some kind of behavioral health therapy. This study will assess participant response to a bundled-care approach to chronic bladder pain both pre-and post intervention as well as compared to a group of participants receiving typical care.

NCT ID: NCT05643157 Recruiting - Clinical trials for Interstitial Cystitis, Chronic

Cellular Scale Measures of Short-Term Retinal Atrophy Progression

Start date: November 1, 2022
Phase:
Study type: Observational

Our goal is to determine the cellular scale changes that occur in subjects who have disease progression due to pentosan polysulfate sodium toxicity

NCT ID: NCT05630742 Completed - Clinical trials for Interstitial Cystitis, Bladder Pain Syndrome, Quality of Life

Quality of Life Analysis in Bladder Pain Syndrome/Interstitial Cystitis

BPS/IC
Start date: November 1, 2021
Phase:
Study type: Observational

The aim of our study was to evaluate whether there is a higher prevalence of anxiety-depressive disorders in women with interstitial cystitis than in women with chronic non-neoplastic pain with or without fibromyalgia, to examine possible correlations between urological and psychiatric symptoms, analyze how urological symptoms affect psychological dimension, and how specific stress or trauma can contribute to the onset of interstitial cystitis.

NCT ID: NCT05544695 Recruiting - Clinical trials for Interstitial Cystitis and Bladder Pain Syndrome

Real-world Evidence Study on Cystistat

IC/BPS
Start date: October 21, 2022
Phase:
Study type: Observational

This study will be conducted with the aim of ensuring the continued acceptability of the benefit-risk ratio and confirming the safety and performance of the device throughout its expected lifetime. Cystistat is supplied as a 50 mL solution containing 40 mg of sodium hyaluronate. It is indicated for the temporary replacement of the GAG layer in the bladder.

NCT ID: NCT05518864 Recruiting - Clinical trials for Bladder Pain Syndrome

GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis (GETSBI Study)

GETSBI
Start date: October 21, 2021
Phase: Phase 4
Study type: Interventional

Rationale: Efficacy study (RCT) for glycosaminoglycan(GAG)-therapy for the indication bladder pain syndrome / interstitial cystitis with Hunner lesion subtype (BPS-IC H+). reason for this study is a current lack of evidence regarding its efficacy and cost-effectiveness. Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain and Quality of Life (QOL)